May 21, 2024 · GSK plc (LSE/NYSE: GSK) today announced positive headline results from the phase III clinical trials SWIFT-1 and SWIFT-2, which assessed the efficacy and safety of …

Oct 14, 2024 · GSK plc (LSE/NYSE: GSK) today announced positive headline results from the phase III clinical trials ANCHOR-1 and ANCHOR-2, which assessed the efficacy and safety of …

3 days ago · ANCHOR-1 and -2 showed depemokimab reduced nasal polyp size and obstruction compared to placebo GSK plc (LSE/NYSE: GSK) today announced that the European …

Sep 9, 2024 · Depemokimab reduced the annualized rate of exacerbations among patients with severe asthma with an eosinophilic phenotype. (Funded by GSK; SWIFT-1 and SWIFT-2 …

5 days ago · The company says new IL-5 inhibitor depemokimab (formerly GSK3511294) has the potential to become the first ultra-long-acting biologic for severe asthma with a six-monthly …

2 days ago · SWIFT-1 and -2 showed depemokimab reduced exacerbation and hospitalisation rates as an add-on therapy for patients with asthma with type 2 inflammation ANCHOR-1 and …

Sep 9, 2024 · GSK’s twice-yearly depemokimab reduced asthma attacks by half and cut clinic visits by nearly three-quarters, positioning it for an estimated $4 billion in peak sales if approved.

Oct 14, 2024 · Depemokimab is a monoclonal antibody that blocks human interleukin-5 (IL-5) binding to its receptor, and GSK pointed out in this morning’s release that IL-5 is present at high...

Oct 14, 2024 · On Monday, GSK plc (NYSE: GSK) released headline results from the phase 3 trials ANCHOR-1 and ANCHOR-2, which assessed the efficacy and safety of depemokimab …

Jan 23, 2025 · GSK's new long-acting drug candidate for severe asthma, depemokimab, reduced the rate of severe attacks by 54% in a pair of phase 3 trials presented at the European …